Your browser doesn't support javascript.
loading
Comparative assessment of outcomes and adverse effects using two different intramuscular testosterone therapy regimens: 100 mg IM weekly or 200 mg IM biweekly.
El-Khatib, Farouk M; Huynh, Linda M; Kopelevich, Alexei; Osman, Mohamad M; Choi, Edward; Nguyen, Jeanie T; Dianatnejad, Sharmin; Wu, Qiaqia; Olivas, Madeline G; Spitz, Aaron; Lowry, Jacob; Losso, Boriss Y; Khera, Mohit; Angulo-Llanos, Laura; Patel, Premal; Ramasamy, Ranjith; Yafi, Faysal A.
Afiliación
  • El-Khatib FM; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Huynh LM; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Kopelevich A; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Osman MM; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Choi E; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Nguyen JT; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Dianatnejad S; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Wu Q; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Olivas MG; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Spitz A; Department of Urology, University of California, Irvine Health, Orange, CA, USA.
  • Lowry J; Department of Urology, Baylor College of Medicine Houston, Houston, TX, USA.
  • Losso BY; Department of Urology, Baylor College of Medicine Houston, Houston, TX, USA.
  • Khera M; Department of Urology, Baylor College of Medicine Houston, Houston, TX, USA.
  • Angulo-Llanos L; Department of Urology, University of Miami Health System in Florida, Miami, FL, USA.
  • Patel P; Department of Urology, University of Miami Health System in Florida, Miami, FL, USA.
  • Ramasamy R; Department of Urology, University of Miami Health System in Florida, Miami, FL, USA.
  • Yafi FA; Department of Urology, University of California, Irvine Health, Orange, CA, USA. fyafi@hs.uci.edu.
Int J Impot Res ; 34(6): 558-563, 2022 Sep.
Article en En | MEDLINE | ID: mdl-34257404
This study aimed to compare the change in levels of several laboratory values and the development of adverse events using two commonly used intramuscular testosterone therapy regimens. Men were included if they were 18 years or older and received one of the following testosterone therapy regimens: 100 mg intramuscular once weekly or 200 mg intramuscular once every other week. Primary outcomes were relative changes in total testosterone, free testosterone, estradiol, prostate-specific antigen, and hematocrit at 6 months after initiation of testosterone therapy. Secondary outcomes were any significant rises in estradiol, hematocrit, prostate-specific antigen, and any other treatment-related adverse events requiring cessation of testosterone therapy. A total of 263 men were enrolled. In a subanalysis of men who had a baseline hematocrit below 54% before intramuscular testosterone therapy initiation, we found the following: men who received 100 mg weekly injections were significantly less likely to have hematocrit levels rising above 54% (1/102 (1%) vs. 4/51 (8%); p = 0.023). No significant differences were recorded in the increase in total testosterone, free testosterone, prostate-specific antigen, and estradiol levels between both groups. A higher average serum testosterone over the dosing interval seen with the 200 mg regimen appears to be associated with a higher risk of erythrocytosis.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Testosterona / Hipogonadismo Límite: Humans / Male Idioma: En Revista: Int J Impot Res Asunto de la revista: MEDICINA REPRODUTIVA / UROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Testosterona / Hipogonadismo Límite: Humans / Male Idioma: En Revista: Int J Impot Res Asunto de la revista: MEDICINA REPRODUTIVA / UROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido